

Boris Cvek

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1551356/boris-cvek-publications-by-citations.pdf>

Version: 2022-10-05

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

980
citations

12
h-index

30
g-index

30
ext. papers

1,081
ext. citations

7.1
avg. IF

4.33
L-index

#	Paper	IF	Citations
25	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017 , 552, 194-199	47.1	294
24	Ni(II), Cu(II), and Zn(II) diethyldithiocarbamate complexes show various activities against the proteasome in breast cancer cells. <i>Journal of Medicinal Chemistry</i> , 2008 , 51, 6256-8	7.8	163
23	A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. <i>Oncotarget</i> , 2013 , 4, 502-30	3.1	131
22	Deubiquitinases (DUBs) and DUB inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2015 , 25, 1191-1208	6.4	68
21	Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram). <i>Drug Discovery Today</i> , 2012 , 17, 409-12	8.3	65
20	The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?. <i>Drug Discovery Today</i> , 2008 , 13, 716-22	8.3	62
19	Diethyldithiocarbamate complex with copper: the mechanism of action in cancer cells. <i>Mini-Reviews in Medicinal Chemistry</i> , 2012 , 12, 1184-92	3	51
18	The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib. <i>Current Pharmaceutical Design</i> , 2011 , 17, 1483-99	3.1	35
17	Proteasome inhibitors. <i>Progress in Molecular Biology and Translational Science</i> , 2012 , 109, 161-226	3.8	23
16	Linking the activity of bortezomib in multiple myeloma and autoimmune diseases. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 61-70	6.7	15
15	Symmetric Ni(II) dithiocarbamates with bidentate phosphines ligands. <i>Journal of Coordination Chemistry</i> , 2006 , 59, 911-919	1.5	14
14	Diethyldithiocarbamate complexes with metals used as food supplements show different effects in cancer cells. <i>Journal of Applied Biomedicine</i> , 2014 , 12, 301-308	0.6	13
13	Searching for Positive Side Effects of Common Drugs. <i>Trends in Pharmacological Sciences</i> , 2017 , 38, 111	12.7	12
12	Nickel(II) di(pentyl)dithiocarbamates with P ligands. <i>Journal of Coordination Chemistry</i> , 2003 , 56, 1123-1129	12.9	10
11	Examination of Zolpidem effects on AhR- and PXR-dependent expression of drug-metabolizing cytochromes P450 in primary cultures of human hepatocytes. <i>Toxicology Letters</i> , 2009 , 191, 74-8	4.1	5
10	Antabuse (disulfiram) as a pilot case of nonprofit drug. <i>International Journal of Cancer</i> , 2010 , 127, 2486	7.2	4
9	Antabuse repurposing: We need more knowledge and wide international support. <i>International Journal of Cancer</i> , 2011 , 129, 1286-1287	7.2	3

8	The Raffles Dialogue on Human Wellbeing and Security. <i>The Lancet Global Health</i> , 2016 , 4, e92	11.9	2
7	TNF-alpha could be responsible for disulfiram-mediated hepatotoxicity. <i>Journal of Hepatology</i> , 2008 , 49, 865-6	3	2
6	Failure of ditiocarb (diethyldithiocarbamate) therapy: was diet the reason?. <i>Current HIV Research</i> , 2009 , 7, 254	1.3	2
5	Drug Repurposing for Terminal-Stage Cancer Patients. <i>American Journal of Public Health</i> , 2016 , 106, e3	4.8	1
4	Low-Income Countries And Repurposed Drugs. <i>Health Affairs</i> , 2015 , 34, 2004	6.6	1
3	Opposite effects of two zinc(II) dithiocarbamates on NF-kB pathway. <i>Nature Precedings</i> , 2007 ,		1
2	Promoting Medical Innovation. <i>Health Affairs</i> , 2017 , 36, 1518	6.6	
1	Combating endometriosis by blocking proteasome and nuclear factor-kappaB pathways. <i>Human Reproduction</i> , 2009 , 24, 2967; author reply 2967-8	5.5	